PT-141 / Bremelanotide
Melanocortin receptor agonist (MC1R & MC4R) acting centrally to modulate neural pathways involved in sexual response. Unlike PDE5 inhibitors, it acts on the nervous system rather than the vascular system.
Indications & Usage
FDA LABEL INDICATIONS
VYLEESI®- ▸ Target: Premenopausal women.
- ▸ Condition: Acquired, generalized Hypoactive Sexual Desire Disorder (HSDD).
- ▸ Mechanism: Non-selective agonist activating MC4R in the hypothalamus.
OFF-LABEL / FUNCTIONAL USE
CLINICAL PRACTICE- ▸ Target: Men & Women (Post-menopausal).
- ▸ Condition: Erectile Dysfunction (non-responsive to PDE5i), Anorgasmia, SSRI-induced sexual dysfunction.
- ▸ Synergy: Often combined with PDE5 inhibitors (Tadalafil/Sildenafil) for synergistic central/peripheral effect.
Dosing Protocols
Select administration route to view specific protocols.
SUBCUTANEOUS INJECTION
GOLD STANDARDStandard Dosage
Administered subcutaneously into abdomen or thigh.
Titration Strategy
Start with 0.5mg - 1.0mg test dose to assess nausea tolerance. Titrate up to 1.75mg if needed. Doses >2mg increase side effect risk without significant efficacy gain.
Timing & Onset
- Onset of Action 45 mins
- Peak Effect 3 - 4 hours
- Duration Up to 24 hrs
Nausea is the primary dose-limiting side effect (approx 40% of patients). Pre-treatment with BPC-157 or Antihistamines may mitigate this.
Pharmacokinetics Profile
Cycling & Safety Limits
The "24/72/8" Rule
Wait 24 Hours
Minimum time between doses to avoid accumulation and sustained hypertension.
Ideally 72 Hours
Optimal washout period to prevent MC4 receptor downregulation (tolerance buildup).
Max 8 / Month
Do not exceed 8 doses per month to ensure long-term efficacy and safety.